Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00256854
Status:
COMPLETED
Last Update Posted:
2019-03-15
First Post:
2005-11-21
Brief Title:
Converting From Ropinirole Immediate Release IR To Ropinirole Controlled-Release for RLS Restless Legs Syndrome
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A 4-Week Randomized Double-Blind Cohort Study to Evaluate the Safety and Tolerability of Converting From Ropinirole Immediate Release IR to Ropinirole Controlled Release for RLS CR-RLS Formulation Formerly Ropinirole Extended Release XR in Patients With Restless Legs Syndrome RLS
Status:
COMPLETED
Status Verified Date:
2018-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multi-center Phase III study to evaluate the safety and tolerability of proposed dose conversion recommendations for RLS subjects converting from ropinirole immediate release to ropinirole controlled-release for RLS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None